UCLA-led research on telomerase could lead to new strategies for treating disease
An enzyme called telomerase plays a significant role in aging and most cancers, but until recently many aspects of the enzyme’s structure could not be clearly seen.
Now, scientists from UCLA and UC Berkeley have produced images of telomerase in much higher resolution than ever before, giving them major new insights about the enzyme. Their findings, published online today by the journal Science, could ultimately lead to new directions for treating cancer and preventing premature aging.
“Many details we could only guess at before, we can now see unambiguously, and we now have an understanding of where the different components of telomerase interact,” said Juli Feigon, a professor of chemistry and biochemistry in the UCLA College and a senior author of the study. “If telomerase were a cat, before we could see its general outline and the location of the limbs, but now we can see the eyes, the whiskers, the tail and the toes.”
The research brought together experts in structural biology, biochemistry and biophysics, and a wide range of cutting-edge research techniques.
Telomerase’s primary job is to maintain the DNA in telomeres, the structures at the ends of our chromosomes that act like the plastic tips at the ends of shoelaces. When telomerase isn’t active, each time our cells divide, the telomeres get shorter. When that happens, the telomeres eventually become so short that the cells stop dividing or die.
On the other hand, cells with abnormally active telomerase can constantly rebuild their protective chromosomal caps and become immortal. Making cells immortal might sound like a promising prospect, but it actually is harmful because DNA errors accumulate over time, which damages cells, said Feigon, who also is a researcher at UCLA’s Molecular Biology Institute and an associate member of the UCLA–Department of Energy Institute of Genomics and Proteomics.
Telomerase is particularly active in cancer cells, which helps make them immortal and enables cancer to grow and spread. Scientists believe that controlling the length of telomeres in cancer cells could be a way to prevent them from multiplying.
When Feigon began her research on telomerase slightly more than a decade ago, she merely wanted to learn how telomerase works; fighting cancer and slowing the aging process were not even in the back of her mind.
“Our research may make those things achievable, even though they were not our goals,” she said. “You never know where basic research will go. When telomerase and telomeres were discovered, no one had any idea what the impact of that research would be. The question was, ‘How are the ends of our chromosomes maintained?’ We knew there had to be some activity in the cell that does that.”
Earlier research led by UC San Francisco professor Elizabeth Blackburn revealed that telomerase was responsible for this activity, but the study didn’t connect telomerase to cancer and it provided little information about its structural biology. The research was conducted using tiny, single-celled microorganisms called Tetrahymena thermophila that are commonly found in freshwater ponds. Blackburn won a Nobel Prize in 2009 for the finding.
Since then, Feigon and her colleagues have been filling in pieces of the telomerase puzzle, also using Tetrahymena. Their latest study found that the microorganism’s telomerase is more analogous to human telomerase than previously thought.
“This is the first time that a whole telomerase directly isolated from its natural workplace has been visualized at a sub-nanometer resolution and all components are identified in the structure,” said Jiansen Jiang, the study’s co-lead author and a UCLA postdoctoral scholar. (A nanometer is equivalent to one billionth of a meter.)
Among the new insights the team reported:
- Scientists had thought telomerase contains eight sub-units: seven proteins and an RNA. But Feigon and her colleagues discovered two additional proteins, Teb2 and Teb3, that increase telomerase’s activity. “Knowing we were the first people in the world who knew about these new proteins was amazing,” she said. “Days like that are what scientific discovery is all about, and it’s exhilarating.”
- Feigon’s research team knew that the RNA strand interacts with the proteins, but not exactly where it interacted. The new study found that within the enzyme’s “catalytic core,” which is formed by the RNA and its partner proteins TERT and p65, the RNA forms a ring around the donut-shaped TERT protein.
- Scientists previously knew that telomerase contains three proteins, p75, p45 and p19, but their structures and functions were poorly understood. The new research identified the proteins’ structures and revealed that they are similar to proteins found at human telomeres.
- The researchers showed that a key protein called p50 interacts with several components of telomerase, including TERT, Teb1 and p75, and this network of interactions has important implications for telomerase’s function.
Feigon knew that the Tetrahymena enzyme’s catalytic core, where the majority of the telomerase activity occurs, was a close analogue to the catalytic core in the human enzyme, but she did not previously know whether the other proteins had human counterparts.
“It turns out that nearly all, if not all, of the telomerase proteins in Tetrahymena have similar proteins in humans,” Feigon said. “Now we can use our model system to learn more about how telomerase interacts at the telomeres.”
Feigon and her colleagues are working to fill in even more details of the telomerase puzzle. Their research could lead to the development of pharmaceuticals that target specific sub-units of telomerase and disrupt interactions between proteins.
“There is so much potential for treating disease if we understand deeply how telomerase works,” Feigon said.
The Latest on: Telomerase
via Google News
The Latest on: Telomerase
- Dutch families reveal human ‘cancer suppression system’on December 2, 2020 at 11:34 am
Telomere shortening, long thought an unwanted side-effect of aging, actually protects against cancer in humans, a new study indicates.
- Researchers develop telomerase gene therapy for treating different pathologieson December 1, 2020 at 10:35 pm
After several years of research and many joint scientific publications, molecular biologists Maria Blasco (National Cancer Research Centre, CNIO) and Fàtima Bosch (Universitat Autònoma de Barcelona, ...
- Telomere shortening helps prevent cancer in humanson December 1, 2020 at 5:12 pm
As time goes by, the tips of your chromosomes--called telomeres--become shorter. This process has long been viewed as an unwanted side-effect of aging, but a recent study shows it is in fact good for ...
- Telomere shortening protects against canceron December 1, 2020 at 12:31 pm
As time goes by, the tips of your chromosomes—called telomeres—become shorter. This process has long been viewed as an unwanted side-effect of aging, but a recent study shows it is in fact good for ...
- A new spin-off company to develop the first treatment against pulmonary fibrosis based on telomeraseon December 1, 2020 at 9:43 am
Maria Blasco from the Spanish National Cancer Research Centre (CNIO, Madrid) and Fàtima Bosch from the Universitat Autònoma de Barcelona (UAB, Barcelona) have founded the new 'Telomere Therapeutics', ...
- Telomeres and Telomerases in Canceron November 27, 2020 at 4:00 pm
Chin Allison,  also of Geron Corp. in Menlo Park, California, is investigating the anticancer effects of GRN163 in multiple myeloma cells, since telomerase is upregulated in these tumors and ...
- Israeli scientists claim they’ve partially REVERSED cellular aging process for 1st time in historyon November 20, 2020 at 2:54 am
Researchers in Israel claim to have partially reversed cellular aging using a somewhat controversial treatment. While only a small study, it improves our understanding of the aging process in humans.
- Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemiaon November 18, 2020 at 4:00 pm
Imetelstat, a 13-mer oligonucleotide that is covalently modified with lipid extensions, competitively inhibits telomerase enzymatic activity. It has been shown to inhibit megakaryocytic ...
- Geron Corporation (GERN) John Scarlett Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)on November 17, 2020 at 3:06 pm
First of all, we are developing an imetelstat, which is the first-in-class telomerase inhibitor, and we will talk in the next slide, next several slides, a little bit about the unique mechanism of ...
- Derek J. Taylor, PhDon November 9, 2020 at 5:50 am
A primary focus of the Taylor lab is to understand the molecular architecture and functional interactions that regulate human telomeres and telomerase. We are particularly interested in understanding ...
via Bing News